Covance Expands Bioanalytical Services for BiologicsBy
The contract research organization Covance Inc. is expanding its global bioanalytical footprint and adding scientific leaders to its biologics team. The company is expanding its large-molecule bioanalytical space co-located with Covance's central laboratory facility in Indianapolis, Indiana. The expansion, which is planned to open during the second half of 2014, is doubling the company's large- molecule capacity and is expected to add approximately 100 new positions over the next five years.
As part of the ongoing investment in biologics, the company also appointed Mike Holsapple, PhD., as Covance's executive director of global immunotoxicology. Dr. Holsapple is a fellow in the Academy of Toxicological Sciences and past president of the Society of Toxicology and has more than 30 years of experience in this field. In conjunction with this appointment, Covance has launched molecule-management teams of scientific leaders who work closely with clients to develop and implement tailored solutions for the development of their biologics.